HNSCC patients are frequently treated with DNA damaging therapies (i.e. radiation and cisplatin), and because our data show that low STING expression is associated with therapeutic resistance, we sought to probe HNSCC patient outcomes dichotomized by STING levels. Here, STING1 is linked to head and neck squamous cell carcinoma.